Development of Dual Chitinase Inhibitors as Potential New Treatment for Respiratory System Diseases
作者:Marzena Mazur、Barbara Dymek、Robert Koralewski、Piotr Sklepkiewicz、Sylwia Olejniczak、Marcin Mazurkiewicz、Michał Piotrowicz、Magdalena Salamon、Karol Jędrzejczak、Agnieszka Zagozdzon、Wojciech Czestkowski、Krzysztof Matyszewski、Bartłomiej Borek、Agnieszka Bartoszewicz、Elżbieta Pluta、Aleksandra Rymaszewska、Witold Mozga、Filip Stefaniak、Paweł Dobrzański、Karolina Dzwonek、Jakub Golab、Adam Golebiowski、Jacek Olczak
DOI:10.1021/acs.jmedchem.9b00681
日期:2019.8.8
Acidic mammalian chitinase (AMCase) and chitotriosidase-1 (CHIT1) are two enzymatically active proteins produced by mammals capable of cleaving the glycosidic bond in chitin. Based on the clinical findings and animal model studies, involvement of chitinases has been suggested in several respiratory system diseases including asthma, COPD, and idiopathic pulmonary fibrosis. Exploration of structure-activity
酸性哺乳动物几丁质酶(AMCase)和壳三糖苷酶-1(CHIT1)是哺乳动物能够在几丁质中切割糖苷键的两种酶促活性蛋白。基于临床研究结果和动物模型研究,几丁质酶参与了多种呼吸系统疾病,包括哮喘,COPD和特发性肺纤维化。探索1-(3-氨基-1H-1,2,4-三唑-5-基)-哌啶-4-胺系列中的结构活性关系,该系列先前被确定为有效的AMCase抑制剂支架,使我们发现了具有非常好的药代动力学特性的高活性双重抑制剂(即AMCase和CHIT1)。他们之中,口服给药后(50 mg / kg,qd),化合物30显示减少了用屋尘螨提取物攻击的小鼠支气管肺泡灌洗液中的细胞总数。另外,与较早报道的几丁质酶抑制剂相比,对化合物30对hERG钾通道的亲和力显着降低。